Urist Marshall's Form 4 filing
Royalty Pharma plc (RPRX) · filed Feb 24, 2023
- Accession no.
- 0001209191-23-012883
- Filed
- Feb 24, 2023
- Trade date
- Feb 22, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market sales total $870.3K. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Urist MarshallCIK 0001838139 | Officer (EVP, Research & Investments) |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 22, 2023 | Class A Ordinary Shares | SSaleDisposed | −23,333 | $37.30F1 | −$870,320.9 | 46,667 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
- F1
The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $37.19 to $37.56 per share. The holder undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon written request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Referenced by the price of 1 transaction in Table I.
Remarks
All reported transactions were effected pursuant to a 10b5-1 plan adopted by the reporting person on December 30, 2022.